Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

USA - NASDAQ:EVGN - IL0011050551 - Common Stock

1.25 USD
+0.01 (+0.81%)
Last: 11/12/2025, 8:17:12 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to EVGN. EVGN was compared to 531 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EVGN has reported negative net income.
In the past year EVGN has reported a negative cash flow from operations.
EVGN had negative earnings in each of the past 5 years.
EVGN had a negative operating cash flow in each of the past 5 years.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -42.01%, EVGN perfoms like the industry average, outperforming 57.44% of the companies in the same industry.
Industry RankSector Rank
ROA -42.01%
ROE N/A
ROIC N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

Looking at the Gross Margin, with a value of 46.76%, EVGN is in the better half of the industry, outperforming 74.95% of the companies in the same industry.
In the last couple of years the Gross Margin of EVGN has declined.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
EVGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EVGN has less shares outstanding
EVGN has a worse debt/assets ratio than last year.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -12.64, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
EVGN has a Altman-Z score of -12.64. This is in the lower half of the industry: EVGN underperforms 76.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.64
ROIC/WACCN/A
WACC5.3%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

EVGN has a Current Ratio of 1.89. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EVGN (1.89) is worse than 77.97% of its industry peers.
EVGN has a Quick Ratio of 1.76. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
EVGN's Quick ratio of 1.76 is on the low side compared to the rest of the industry. EVGN is outperformed by 78.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.76
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.18% over the past year.
EVGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.72%.
Measured over the past years, EVGN shows a very strong growth in Revenue. The Revenue has been growing by 62.55% on average per year.
EPS 1Y (TTM)43.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
Revenue 1Y (TTM)-28.72%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-3.28%

3.2 Future

The Earnings Per Share is expected to grow by 19.84% on average over the next years. This is quite good.
The Revenue is expected to decrease by -9.70% on average over the next years.
EPS Next Y29.49%
EPS Next 2Y28.03%
EPS Next 3Y19.84%
EPS Next 5YN/A
Revenue Next Year-56.03%
Revenue Next 2Y-29.71%
Revenue Next 3Y-9.7%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as EVGN's earnings are expected to grow with 19.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.03%
EPS Next 3Y19.84%

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (11/12/2025, 8:17:12 PM)

1.25

+0.01 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-19 2025-08-19/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners1.66%
Inst Owner Change0%
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap10.90M
Revenue(TTM)6.74M
Net Income(TTM)-14.25M
Analysts82.86
Price Target2.55 (104%)
Short Float %1.14%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.82%
Min EPS beat(2)3.52%
Max EPS beat(2)18.12%
EPS beat(4)3
Avg EPS beat(4)25.65%
Min EPS beat(4)-27.16%
Max EPS beat(4)108.11%
EPS beat(8)7
Avg EPS beat(8)24.47%
EPS beat(12)11
Avg EPS beat(12)24.66%
EPS beat(16)12
Avg EPS beat(16)17.11%
Revenue beat(2)0
Avg Revenue beat(2)-14.98%
Min Revenue beat(2)-23.14%
Max Revenue beat(2)-6.81%
Revenue beat(4)0
Avg Revenue beat(4)-31.15%
Min Revenue beat(4)-56.44%
Max Revenue beat(4)-6.81%
Revenue beat(8)4
Avg Revenue beat(8)16.37%
Revenue beat(12)6
Avg Revenue beat(12)40.72%
Revenue beat(16)8
Avg Revenue beat(16)42.34%
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.4%
EPS NY rev (1m)-0.7%
EPS NY rev (3m)2.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.62
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0.77
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.76%
FCFM N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.7%
Cap/Sales 8.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.76
Altman-Z -12.64
F-Score2
WACC5.3%
ROIC/WACCN/A
Cap/Depr(3y)33.47%
Cap/Depr(5y)32.69%
Cap/Sales(3y)30.31%
Cap/Sales(5y)49.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
EPS Next Y29.49%
EPS Next 2Y28.03%
EPS Next 3Y19.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.72%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-3.28%
Revenue Next Year-56.03%
Revenue Next 2Y-29.71%
Revenue Next 3Y-9.7%
Revenue Next 5YN/A
EBIT growth 1Y9.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.44%
EBIT Next 3Y20.31%
EBIT Next 5YN/A
FCF growth 1Y15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.68%
OCF growth 3YN/A
OCF growth 5YN/A

EVOGENE LTD / EVGN FAQ

Can you provide the ChartMill fundamental rating for EVOGENE LTD?

ChartMill assigns a fundamental rating of 1 / 10 to EVGN.


What is the valuation status for EVGN stock?

ChartMill assigns a valuation rating of 0 / 10 to EVOGENE LTD (EVGN). This can be considered as Overvalued.


How profitable is EVOGENE LTD (EVGN) stock?

EVOGENE LTD (EVGN) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for EVGN stock?

The Earnings per Share (EPS) of EVOGENE LTD (EVGN) is expected to grow by 29.49% in the next year.